(Total Views: 775)
Posted On: 05/29/2024 2:51:59 AM
Post# of 155052
Hey Ohm,
sorry to attempt to leverage your scientific expertise, but what do you think about Insmed's brensocatib relative to our drug, ref link and a couple exerts below? thanks
"succeeded in an final-phase study... The results validate Insmed's theory that blocking an enzyme called DPP1 can help treat some inflammatory diseases..
... analyst compared the market potential for Insmed's brensocatib to Regeneron and Sanofi's Dupixent and AbbVie's Humira. Dupixent, a treatment for asthma, eczema and other diseases, brought $11.6 billion in sales last year. Analysts expect it to top $21 billion in 2029 sales. At its peak in 2022, Humira generated $21.2 billion in sales from treating patients with immunological diseases.
"However, diagnosed NCFB may just be the tip of the iceberg, ..."
https://www.investors.com/news/technology/ins...8:13:3 src="/m/images/icons/icon_biggrin.gif" class="post_smiley" /> A:2&j=2974364&sfmc_sub=93265278&l=222_HTML&u=42316531&mid=100016628&jb=13002
sorry to attempt to leverage your scientific expertise, but what do you think about Insmed's brensocatib relative to our drug, ref link and a couple exerts below? thanks
"succeeded in an final-phase study... The results validate Insmed's theory that blocking an enzyme called DPP1 can help treat some inflammatory diseases..
... analyst compared the market potential for Insmed's brensocatib to Regeneron and Sanofi's Dupixent and AbbVie's Humira. Dupixent, a treatment for asthma, eczema and other diseases, brought $11.6 billion in sales last year. Analysts expect it to top $21 billion in 2029 sales. At its peak in 2022, Humira generated $21.2 billion in sales from treating patients with immunological diseases.
"However, diagnosed NCFB may just be the tip of the iceberg, ..."
https://www.investors.com/news/technology/ins...8:13:3
(1)
(0)
